{"nct_id":"NCT04068181","title":"Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).","status":"COMPLETED","status_verified_date":"2024-11","start_date":"2020-01-22","start_date_type":"ACTUAL","primary_completion_date":"2021-08-19","primary_completion_date_type":"ACTUAL","completion_date":"2024-02-26","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["AMGN"]}